*Indicated for use in pediatric patients pediatric patients ages 6 to 17 years. *Use in these age groups is based on one adequate and well-controlled clinical study in pediatric patients 6 to 12 years old, pharmacokinetic data in adolescents and adults, and safety information from other methylphenidate-containing products. *The safety and effectiveness of in pediatric patients under six years have not been evaluated. *Long-term effectiveness of QuilliChew ER has not been established. *Growth should be monitored during treatment with CNS stimulants, including QuilliChew ER. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted. *Information on dosing, adverse events, clinical trial. *New dosage form.
|